Oral dehydroepiandrosterone vs placebo
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes onlyRR 10.5 [3.26, 33.75]1 study · 381 participantsModerate